Skip to content

The role of EMG biofeedback in the treatment of depression in old age with comorbid chronic pain syndrome (EMBRACE)

The role of EMG biofeedback in the treatment of depression in old age with comorbid chronic pain syndrome (EMBRACE) - EMBRACE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035678
Enrollment
42
Registered
2025-04-30
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32

Interventions

Group 1: monocentric, prospective, single-arm pilot study EMG biofeedback intervention: EMG-BF facilitates neuromuscular training and muscle relaxation by using acoustic and visual stimuli using a bi

Sponsors

LVR-Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität Düsseldorf Bergische Landstraße 2
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: Knowledge of the German language, both written and spoken - Presence of a written consent form

Exclusion criteria

Exclusion criteria: Surgery on the affected body part in the last 12 months - Acute pain symptoms that require surgical treatment - Pregnancy - Severe hearing or vision impairment - Presence of a non-orthopedic cause for the pain, e.g. (malignant) tumors, infections including osteomyelitis), fractures, inflammatory/rheumatic diseases - Presence of active cancer treatment in the sense of chemotherapy or radiotherapy - Chronic neurological diseases (e.g. Parkinson's syndrome) or neurodegenerative diseases (e.g. dementia) - Presence of a spinal cord stimulator (spinal cord stimulation), an intrathecal medication pump or peripheral nerve stimulation - Therapeutic nerve block, spinal injection or other anesthesiological procedure to treat pain symptoms in the last 12 months - Presence of a disease that could interfere with the performance of the QST - Serious physical disability that makes testing impossible - Unstable or untreated cardiopulmonary diseases - Serious, unstable psychiatric diseases (e.g. schizophrenia, delusional disorder, manic or dissociative disorder) - Current substance abuse/dependence - Diseases or recent medical interventions that at the discretion of the study director, may interfere with participation in the study - Known plaster allergy - Subjects who are included in other studies at the same time

Design outcomes

Primary

MeasureTime frame
-Recruitment: Number of recruited participants compared to the planned target number. -Completion Rate: Percentage of participants who completed the study compared to the total number of participants enrolled. -Adherence: Compliance with specific requirements or protocols during participation, such as completing questionnaires or attending therapy sessions. The following questionnaires will be used for the project before and after the intervention (a total of two): 1. Generalized Anxiety Disorder-7 Scale (GAD-7) 2. Chronic Pain Acceptance Questionnaire (CPAQ-D) 3. Childhood Trauma Screener (CTS) 4. Beck Depression Inventory (BDI-II) 5. Brief Pain Inventory (BPI) 6. Pain Catastrophizing Scale (PCS)

Secondary

MeasureTime frame
-Pain intensity -Pain interference -Pressure pain threshold.

Countries

Germany

Contacts

Public ContactMyrella Paschali

LVR-Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität Düsseldorf

Myrella.Paschali@lvr.de+49(211)922-4233

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026